Close
Blog & Resources Camargo Blog July 15th, 2010

Avandia: Who Won?

The media has been very involved in the Avandia case. Headlines or page 1 stories in the New York Times, Wall Street Journal and the British press seemed to take sides rather than report the facts (okay, I shouldn’t be surprised). Today, the day after the 2-day FDA Advisory Committee met to review the safety concerns about Avandia, we see headlines that generally appear to be aligned with the actual votes:

DIA Website: FDA Panel Votes To Keep Avandia On Market With More Restrictions (no hyperlink since access is by subscription)

NYTimes: F.D.A. Panel Votes to Restrict Avandia (no hyperlink since access is by subscription)

MSN Website: Avandia Raises Heart Risk But Should Stay on Market, FDA Panel Finds

USAToday: Majority of FDA panel votes to keep Avandia on the market

Yet, the articles under the headlines take very different views. For example, the New York Times followed the headline with “..advisory panel recommended.. Avandia…should either be withdrawn from the market or have sales severely restricted because it increases the risks of heart attacks.”

The USAToday articles starts “…a majority of Food and Drug Administration advisory panel members Wednesday did not recommend taking the diabetes drug Avandia off the market, despite evidence showing it raises heart attack risk”.

Hmmm…, what did the FDA advisory committee actually do? There were a number of questions asked of the 33 members, but a key question on what should be done:

12 — withdraw the product from the market

10 — keep on the market with serious warnings

7 – keep on the market with some warnings

3 – keep on the market with no change

1 — abstain

Clearly, a divided opinion (20 keep in some fashion, 12 withdraw) that appears to mirror the divided opinion presented by the FDA in their briefing materials. FDA’s Margaret Hamburg has indicated that she will be the final decision maker since the review division is divided.



Get Our Expertise Working for You

To learn how you can benefit from our regulatory and strategic development expertise, view our solutions or contact us.


Camargo Pharmaceutical Services provides comprehensive drug development solutions, specializing in customized programs including the 505(b)(2) pathway.


Contact
Headquarters
9825 Kenwood Road
Suite 203
Cincinnati OH, 45242
Durham Office
800 Taylor Street
Suite 101, Mill No. 1
Durham NC, 27701
Montreal Office
507 Place d'Armes
Suite 1101
Montreal, QC H2Y 2W8, Canada
Phone 513.561.3329
Toll Free 888.451.5708
Subscribe for our Latest Insights